DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0008537 A1 Wu Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0008537 A1 Wu Et Al US 20060008537A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0008537 A1 Wu et al. (43) Pub. Date: Jan. 12, 2006 (54) METHOD OF TREATING ACNE (22) Filed: Jul. 7, 2004 (76) Inventors: Jeffrey M. Wu, Warrington, PA (US); Publication Classification Jue-Chen Liu, Belle Mead, NJ (US); Jeannette Chantalat, Princeton, NJ (51) Int. Cl. (US); Ying Sun, Belle Mead, NJ (US) A61K 33/04 (2006.01) (52) U.S. Cl. .............................................................. 424/705 Correspondence Address: PHILIP S. JOHNSON JOHNSON & JOHNSON (57) ABSTRACT ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003 (US) The invention features a composition including an anti-acne agent, an antimicrobial agent, and a lactate, and the use (21) Appl. No.: 10/886,314 thereof in the treatment of acne. US 2006/0008537 A1 Jan. 12, 2006 METHOD OF TREATING ACNE made on the product containing the composition or in Stores, magazines, newspaper, radio, television, internet, and the BACKGROUND OF THE INVENTION like. 0001 Acne is a skin disorder that is often accompanied 0010. The compositions of the present invention are by pimples that Sometimes cause acne Sufferers embarrass useful for treating follicular diseases, Such as acne, Sebor ment. Consumers have utilized topical anti-acne agents, rhea, follicular rash, follicular infections Such as folliculitis Such as Salicylic acid and benzoyl peroxide to treat acne for and pSudofolliculitis barbe, follicular ketarosis, keratosis many years. Topical anti-acne agents typically function by pilaris, phrynoderma, ichthyosis follicularis, alopecia, folli exfoliating skin and/or killing bacteria on the Surface of the cular dysplasia, hirsutism, and hypertrichosis. AS used skin. Although Such anti-acne agents are often effective at herein, the term “treating” or “treatment” means the treat treating acne pimples, they tend to take a long time, typically ment (e.g., alleviation or elimination of Symptoms and/or days or weeks, to abate acne symptoms. They are also often cure) and/or prevention or inhibition of the condition (e.g., ineffective at treating pre-emergent pimples. a skin condition). 0011. In one embodiment, the composition is for the SUMMARY OF THE INVENTION treatment of acne, including but not limited to the treatment or prevention of acne blemishes, acne pimples, pre-emergent 0002 The present invention features a composition pimples, blackheads, and/or whiteheads. What is meant by a including an anti-acne agent, an antimicrobial agent, and a “pre-emergent pimple' is an inflamed follicle that are not lactate. The present invention also features a method of Visually apparent on the Surface of the skin with the naked treating a follicular disease, Such as acne, by applying a eye (e.g., as a lesion). In one embodiment, the appearance of composition to an area of skin in need of Such treatment. The acne (e.g., the size and/or appearance of the acne lesion present invention also features a method of promoting a and/or blackhead) is reduced within about eight hours, Such composition by promoting the composition for the treatment as within about four hours. of a follicular disease, Such as acne. 0012. In one embodiment, the present invention relates to 0003. Other features and advantages of the present inven topical compositions including an anti-acne agent. What is tion will be apparent from the detailed description of the meant by an anti-acne agent is an compound that has been invention and from the claims. approved by the U.S. Food and Drug Administration for the topical treatment of acne. Examples of anti-acne agents DETAILED DESCRIPTION OF THE include, but are not limited to, Salicylic acid, benzoyl INVENTION peroxide, Sulphur, retinoic acid, candida bombicola?glucose/ 0004. It is believed that one skilled in the art can, based methyl rapeseedate ferment, peat water, resorcinol, Silt, peat, upon the description herein, utilize the present invention to permethin, azaleic acid, clindamycin, adapalene, erythromy its fullest extent. The following specific embodiments are to cin, Sodium Sulfacetamide, and combinations thereof. In one be construed as merely illustrative, and not limitative of the embodiment, the amount of anti-acne agent in the compo remainder of the disclosure in any way whatsoever. sition is from about 0.01% to about 10%, for example from about 0.1% to about 5%, or from about 0.5% to about 2% by 0005. Unless defined otherwise, all technical and scien weight, based on the total weight of the composition. tific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the 0013 In one embodiment, the compositions of the invention belongs. Also, all publications, patent applica present invention include a hair growth agent. What is meant tions, patents, and other references mentioned herein are by a hair growth agent is a compound that induces hair incorporated by reference. Whenever used, any percentage growth. Examples of hair growth agents include, but are not is weight by weight (w/w) unless otherwise indicated. limited to, minoxadil, Spironolactone, cyproterone acetate, aZeleic acid, buSerelin, bicalutamide, cromakalim, 0006 AS used herein, “topically applying” means cyclosporin, aminoglutethimide, cyproterone acetate, diaz directly laying on or spreading on Outer skin, e.g., by use of oxide, phenytoin, estradiols, flutamide, prezatide copper, the hands or an applicator Such as a wipe, puff, roller, or inocoterone, leuprolide acetate, ketoconazole, pinacidil, Spray. progesterone, finasteride, retinoic acid, turosteride, Vitamins 0007 AS used herein, "cosmetically-acceptable” means and minerals Such as Vitamin E, niacin (vitamin B3), pan that the compound(s) or composition(s) which the term tothenic acid (vitamin B5), pyridoxine (vitamin B6), vitamin describes are Suitable for use in contact with tissues (e.g., the C, biotin, inositol, Zinc, copper, cysteine, methionine, coen skin) without undue toxicity, incompatibility, instability, Zyme Q10, essential fatty acids Such as flaxseed oil, prim irritation, allergic response, and the like. This term is not rose oil, and fish oil, herbal extracts Such as ginko biloba, intended to limit the compound/composition to which it and combinations thereof. describes for use Solely as a cosmetic (e.g., the ingredient/ 0014. In one embodiment, the compositions of the product may be used as a pharmaceutical). present invention include a hair retardation agent. What is meant by a hair retardation agent is a compound that reduces 0008 AS used herein, “safe and effective amount” means the appearance and/or growth of hair. Examples of hair an amount of compound(s) or composition(s) sufficient to retardation agents include, but are not limited to eflornithine treat acne, but low enough to avoid Serious Side effects. hydrochloride, Soy extracts, antiandrogenic Sterols from 0009 What is meant by “promoting” is promoting, Serenoa (Serenoa repens) and/or from Cucurbita Seeds advertising, or marketing. Examples of promoting include, (Cucurbita pepo), dipeptide N-(Carboxymethyl)phenylala but are not limited to, written, Visual, or verbal Statements nyl-B-alanine compounds, 3-deaZaneplanocin, inhibitors of US 2006/0008537 A1 Jan. 12, 2006 nitric oxide Synthetase Such as NG-methyl-L-arginine, drenolide, mometasone furoate, and methylprednisolone inhibitors of glutamine metabolism Such as 6-diazo-5-ox acetate), methotrexate, cyclosporine, calcipotriene, anthra onorleucine (I), and combinations thereof. line, Shale oil, elubiol, ketoconazole, coal tar, Salicylic acid, 0.015. In one embodiment, the compositions of the Zinc pyrithione, Selenium Sulfide, hydrocortisone, Sulfur, present invention include an antimicrobial agent. What is menthol, and pramoxine hydrochloride, and combinations meant by an antimicrobial agent is a compound that kills thereof. microorganisms or prevents or inhibits their growth or 0020. In one embodiment, the compositions of the reproduction. Examples of antimicrobial agents include, but present invention include an anti-Viral agent. Examples of are not limited to: ethanol, propanol, benzalkonium chloride, anti-viral agents include, but are not limited to, imiquimod, benzethonium chloride, methyl benzethonium chloride, podofilox, podophyllin, interferon alpha, acyclovir, famcy cetypyridiunium chloride, 2,4,4-trichloro-2-hydroxy diphe clovir, Valcyclovir, reticulos and cidofovir. nyl ether (Triclosan), parachlorometa Xylenol (PCMX), lodopropynyl butylcarbamate, diazolidinyl urea, chlorhex 0021. In one embodiment, the compositions of the idene digluconate, chlorhexidene acetate, chlorhexidene present invention include an anti-inflammatory agent. isethionate, chlorhexidene hydrochloride, heXetidine, Examples of anti-inflammatory agents, include, but are not Quaternium 15, triclocarbon, polyhexamethylene biguanide, limited to, non-Steroidal and Steroidal anti-inflammatory cetylpyridium chloride, imidazolidinyl urea, diazolidinyl agents Such as corticosteroids Such as hydrocortisone, urea, 3-iodo-2-propynyl-N-butylcarbamate, 2-methyl-4- hydroxyltriamcinolone alphamethyl dexamethasone, dex isothiazolin-3-one, dimethyl dimethyl hydantoin,(5-chloro amethasone-phosphate, beclomethasone dipropionate, clo 2-(2,4-dichlorophenoxy)phenol, monolaurin glyceryl lau betasol Valerate, desonide, desoxymethasone, desoxycorti rate, camelia Sinensis, candida bombicola?glucose/methyl costerone acetate, dexamethasone, dichlorisone, difloraSone rapeseedate ferment, hydrogen peroxide, phenol,
Load more

Recommended publications
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/06 (2006.01) A61K 31/57 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/14 (2006.01) A61K 31/573 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/56 (2006.01) A61K 31/58 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/040560 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 2 June 2014 (02.06.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/830,53 1 3 June 2013 (03.06.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: TOLMAR, INC.
    [Show full text]
  • New Drugs Are Not Enough‑Drug Repositioning in Oncology: an Update
    INTERNATIONAL JOURNAL OF ONCOLOGY 56: 651-684, 2020 New drugs are not enough‑drug repositioning in oncology: An update ROMINA GABRIELA ARMANDO, DIEGO LUIS MENGUAL GÓMEZ and DANIEL EDUARDO GOMEZ Laboratory of Molecular Oncology, Science and Technology Department, National University of Quilmes, Bernal B1876, Argentina Received August 15, 2019; Accepted December 16, 2019 DOI: 10.3892/ijo.2020.4966 Abstract. Drug repositioning refers to the concept of discov- 17. Lithium ering novel clinical benefits of drugs that are already known 18. Metformin for use treating other diseases. The advantages of this are that 19. Niclosamide several important drug characteristics are already established 20. Nitroxoline (including efficacy, pharmacokinetics, pharmacodynamics and 21. Nonsteroidal anti‑inflammatory drugs toxicity), making the process of research for a putative drug 22. Phosphodiesterase-5 inhibitors quicker and less costly. Drug repositioning in oncology has 23. Pimozide received extensive focus. The present review summarizes the 24. Propranolol most prominent examples of drug repositioning for the treat- 25. Riluzole ment of cancer, taking into consideration their primary use, 26. Statins proposed anticancer mechanisms and current development 27. Thalidomide status. 28. Valproic acid 29. Verapamil 30. Zidovudine Contents 31. Concluding remarks 1. Introduction 2. Artesunate 1. Introduction 3. Auranofin 4. Benzimidazole derivatives In previous decades, a considerable amount of work has been 5. Chloroquine conducted in search of novel oncological therapies; however, 6. Chlorpromazine cancer remains one of the leading causes of death globally. 7. Clomipramine The creation of novel drugs requires large volumes of capital, 8. Desmopressin alongside extensive experimentation and testing, comprising 9. Digoxin the pioneer identification of identifiable targets and corrobora- 10.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al
    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • WHO Model List (Revised April 2003) Explanatory Notes
    13th edition (April 2003) Essential Medicines WHO Model List (revised April 2003) Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings. When the strength of a drug is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as". The square box symbol (? ) is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources.
    [Show full text]
  • Hirsutism and Polycystic Ovary Syndrome (PCOS)
    Hirsutism and Polycystic Ovary Syndrome (PCOS) A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee. No portion herein may be reproduced in any form without written permission. This booklet is in no way intended to replace, dictate or fully define evaluation and treatment by a qualified physician. It is intended solely as an aid for patients seeking general information on issues in reproductive medicine. Copyright © 2016 by the American Society for Reproductive Medicine AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Hirsutism and Polycystic Ovary Syndrome (PCOS) A Guide for Patients Revised 2016 A glossary of italicized words is located at the end of this booklet. INTRODUCTION Hirsutism is the excessive growth of facial or body hair on women. Hirsutism can be seen as coarse, dark hair that may appear on the face, chest, abdomen, back, upper arms, or upper legs. Hirsutism is a symptom of medical disorders associated with the hormones called androgens. Polycystic ovary syndrome (PCOS), in which the ovaries produce excessive amounts of androgens, is the most common cause of hirsutism and may affect up to 10% of women. Hirsutism is very common and often improves with medical management. Prompt medical attention is important because delaying treatment makes the treatment more difficult and may have long-term health consequences. OVERVIEW OF NORMAL HAIR GROWTH Understanding the process of normal hair growth will help you understand hirsutism. Each hair grows from a follicle deep in your skin. As long as these follicles are not completely destroyed, hair will continue to grow even if the shaft, which is the part of the hair that appears above the skin, is plucked or removed.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Interactions with Protease Inhibitors Charts Revised February 2018
    www.hiv-druginteractions.org Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium Ertapenem Bupivacaine Erythromycin Cisatracurium Ethambutol Desflurane Ethionamide Dexmedetomidine Flucloxacillin Enflurane Gentamicin Ephedrine Imipenem/Cilastatin Halothane Isoniazid Isoflurane Kanamycin Ketamine Levofloxacin Linezolid Nitrous oxide Meropenem Propofol Metronidazole Rocuronium Moxifloxacin Sevoflurane Nitrofurantoin Sufentanil Ofloxacin Suxamethonium (succinylcholine) Para-aminosalicylic acid Tetracaine Penicillins Thiopental for distribution. for Pyrazinamide Tizanidine Rifabutin Vecuronium Rifampicin Analgesics Rifapentine Alfentanil Rifaximin Aspirin Spectinomycin Buprenorphine Streptomycin Celecoxib Sulfadiazine Codeine Telithromycin Tetracyclines
    [Show full text]
  • CLINICAL REVIEW Management of Hirsutism
    For the full versions of these articles see bmj.com CLINICAL REVIEW Management of hirsutism Olympia Koulouri, Gerard S Conway Department of Endocrinology, Hirsutism is the presence of excess hair growth in that secrete androgens are rare and tend to cause severe University College London women, and the term usually refers to excessive hirsutism. Adrenal tumours usually co-secrete cortisol Hospitals, London NW1 2PQ growth of terminal hair in an androgen dependent dis- and the clinical picture is that of Cushing’s syndrome. Correspondence to: G S Conway [email protected] tribution. Although it is often thought to be a cosmetic At the time of the menopause, hair growth is pro- problem, unwanted hair growth adversely affects psy- moted by a fall in the production of ovarian oestradiol Cite this as: BMJ 2009;338:b847 chological wellbeing.1 It can have a similar effect on but relatively well maintained testosterone production. doi:10.1136/bmj.b847 quality of life scores to that of asthma, epilepsy, and In some instances, rising concentrations of luteinising diabetes,2 and effective treatments reverse these hormone lead to stromal hyperplasia, high testoster- adverse scores.3 one concentrations, and severe menopausal hirsutism. Several new treatments have emerged in recent years, including the wider availability of laser depilation, topi- What aspects of the history and examination are cal suppressors of hair growth (eflornithene), and a pro- important? gestogen with antiandrogenic properties (drospirenone). For research purposes, hair growth can be measured In this review, we assess the evidence base for new treat- using a scoring system established by Ferriman and ments in the context of established treatments, although Gallwey.5 In clinical practice, subjective assessment is the worldwide availability of these preparations varies usually adequate, although personal perception of greatly.
    [Show full text]